Abstract
Nurse practitioners play important roles in breast cancer prevention, early detection, therapeutic efficacy, and surveillance. Assessment of a patient's health status is part of the nine nurse practitioner core competencies updated in 2012 by the National Organization of Nurse Practitioner Faculties. Although adverse events are common in treatment for metastatic breast cancer (MBC), proactive management strategies can limit the number and/or severity of adverse events. Additionally, knowledge of common metastatic sites and clinical signs/symptoms of recurrence provides one of the first-line strategies for successful treatment. We review five case studies of women with MBC who were managed successfully with eribulin mesylate in late lines of therapy after at least two chemotherapeutic regimens for advanced breast cancer that included both an anthracycline and a taxane in either the adjuvant or metastatic setting.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 65-70 |
| Number of pages | 6 |
| Journal | Clinical Medicine Insights: Oncology |
| Volume | 8 |
| DOIs | |
| State | Published - 2014 |
| Externally published | Yes |
Keywords
- Distant breast cancer metastases
- Eribulin
- Eribulin-related AE management
- Metastatic breast cancer
ASJC Scopus subject areas
- Oncology
